ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » New Hampshire » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in New Hampshire

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
MARY-CLAIRE PAICOPOLIS M.D.

Cardiovascular Disease

13,211

$801K

627
513 are 65+

5%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 23%

$61
Average prescription price

Avg: $72

YUKA ENDO M.D.

Cardiovascular Disease

4,253

$227K

320
263 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 23%

$53
Average prescription price

Avg: $72

ALAN GARSTKA MD

Cardiovascular Disease

3,521

$280K

298
264 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 23%

$80
Average prescription price

Avg: $72

ROBERT LAVERY MD

Cardiovascular Disease

3,357

$209K

344
308 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 23%

$62
Average prescription price

Avg: $72

GREGORY GOODKIN MD

Cardiovascular Disease

3,341

$257K

303
274 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 23%

$77
Average prescription price

Avg: $72

WENDI CARDEIRO MD

Cardiovascular Disease

3,239

$184K

280
231 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 23%

$57
Average prescription price

Avg: $72

STEVEN SCHWARTZ MD

Cardiovascular Disease

3,165

$185K

290
249 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 23%

$58
Average prescription price

Avg: $72

WILLIAM DANFORD MD

Cardiovascular Disease

2,946

$142K

270
232 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 23%

$48
Average prescription price

Avg: $72

PETER DOURDOUFIS DO

Cardiovascular Disease

2,910

$185K

269
237 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 23%

$64
Average prescription price

Avg: $72

CARL FIER MD

Cardiovascular Disease

2,619

$488K

222
186 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 23%

$186
Average prescription price

Avg: $72

ALAN ROSENFELD M.D.

Cardiovascular Disease

2,589

$93.4K

208
191 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 23%

$36
Average prescription price

Avg: $72

STEVEN BEAUDETTE M.D.

Cardiovascular Disease

2,544

$152K

315
269 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 23%

$60
Average prescription price

Avg: $72

CARL SZOT M.D.

Cardiovascular Disease

2,498

$122K

337
300 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 23%

$49
Average prescription price

Avg: $72

HUSAM FARAH MD

Cardiovascular Disease

2,477

$79.7K

166
137 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

14%
prescriptions for brand name drugs

Avg: 23%

$32
Average prescription price

Avg: $72

PETER KLEMENTOWICZ M.D.

Cardiovascular Disease

2,423

$220K

256
219 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 23%

$91
Average prescription price

Avg: $72

MARK JACOBS MD

Cardiovascular Disease

2,417

$156K

221
203 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 23%

$65
Average prescription price

Avg: $72

PATRICK HICKLE MD

Cardiovascular Disease

2,408

$145K

278
237 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 23%

$60
Average prescription price

Avg: $72

THOMAS WHARTON MD

Cardiovascular Disease

2,209

$227K

209
194 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

39%
prescriptions for brand name drugs

Avg: 23%

$103
Average prescription price

Avg: $72

ALAN OPSAHL MD

Cardiovascular Disease

2,181

$97.3K

305
264 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 23%

$45
Average prescription price

Avg: $72

MARK LIEBLING

Cardiovascular Disease

2,010

$173K

236
219 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 23%

$86
Average prescription price

Avg: $72

ALAN GLADSTONE MD

Cardiovascular Disease

1,968

$174K

205
188 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 23%

$88
Average prescription price

Avg: $72

JOHN RIEDEL MD FACC

Cardiovascular Disease

1,933

$140K

104
89 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 23%

$72
Average prescription price

Avg: $72

ANDREW TORKELSON MD

Cardiovascular Disease

1,899

$142K

338
310 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 23%

$75
Average prescription price

Avg: $72

EMIL POLLAK M.D.

Cardiovascular Disease

1,834

$98.1K

210
176 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

15%
prescriptions for brand name drugs

Avg: 23%

$53
Average prescription price

Avg: $72

STEPHEN HANLON MD

Cardiovascular Disease

1,824

$107K

282
241 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 23%

$59
Average prescription price

Avg: $72

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank